Patients on any medication need to be aware of any possible drug-drug interactions.
In the July issue of Lancet Oncology, a comprehensive overview of known or suspected drug-drug interactions between tyrosine-kinase inhibitors (Gleevec, Sutent, Stivarga) prescribed for GIST, as well as some that are used for other diagnoses, are identified.
The list includes all 15 TKIs approved to date by the US Food and Drug Administration or the European Medicines Agency.
They are axitinib (Inlyta, Pfizer), crizotinib (Xalkori, Pfizer), dasatinib (Sprycel, Bristol-Myers Squibb and Otsuka America), erlotinib (Tarceva, Osi Pharmaceuticals), gefitinib (Iressa, AstraZeneca), imatinib (Gleevec, Novartis), lapatinib (Tykerb, GlaxoSmithKline), nilotinib (Tasigna, Novartis), pazopanib (Votrient, GlaxoSmithKline), regorafenib (Stivarga, Bayer), ruxolitinib (Jakafi, Incyte), sorafenib (Nexavar, Bayer), sunitinib (Sutent, Pfizer), vandetanib (Caprelsa, AstraZeneca), and vemurafenib (Zelboraf, Roche).
Read more about the Lancet Oncology list in this Medscape article.
More information about drug interactions and a list of inhibitors and inducers of CP3A4 and CP2D6 can be found here.